Sub-depressor dose of angiotensin type-1 receptor blocker inhibits transforming growth factor-beta-mediated perivascular fibrosis in hypertensive rat hearts.
D000284:Administration, Oral; D000804:Angiotensin II / Q000378:metabolism; D047228:Angiotensin II Type 1 Receptor Blockers; D000818:Animals; D001011:Aorta / Q000601:surgery; D001562:Benzimidazoles / Q000494:pharmacology; D001713:Biphenyl Compounds; D003094:Collagen / Q000096:biosynthesis; D003250:Constriction; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004719:Endomyocardial Fibrosis / Q000188:drug therapy* / Q000473:pathology / Q000517:prevention & control; D005347:Fibroblasts / Q000166:cytology / Q000187:drug effects / Q000378:metabolism; D006973:Hypertension / Q000188:drug therapy / Q000503:physiopathology*; D008297:Male; D032383:Myocytes, Cardiac / Q000187:drug effects / Q000473:pathology; D051381:Rats; D017208:Rats, Wistar; D044140:Receptor, Angiotensin, Type 1 / Q000008:administration & dosage*; D013777:Tetrazoles / Q000494:pharmacology; D013997:Time Factors; D016212:Transforming Growth Factor beta / Q000037:antagonists & inhibitors* / Q000096:biosynthesis / Q000187:drug effects; D020257:Ventricular Remodeling / Q000187:drug effects / Q000502:physiology
D047228:Angiotensin II Type 1 Receptor Blockers; D001562:Benzimidazoles; D001713:Biphenyl Compounds; D044140:Receptor, Angiotensin, Type 1; D013777:Tetrazoles; D016212:Transforming Growth Factor beta; D000804:Angiotensin II; D003094:Collagen; C081643:candesartan